Why Capricor Therapeutics (CAPR) Shares Are Trading Lower

Capricor Therapeutics Inc CAPR shares are trading lower by 6.05% to $19.27 during Thursday’s session. The company earlier commenced its public offering of common stock.

What To Know: The company announced the pricing of its public offering of 4.41 million shares at $17.00 per share. The company granted underwriters a 30-day option to purchase an additional 661,800 shares.

The offering, expected to close on October 18, will raise approximately $75 million before expenses and commissions.

Piper Sandler & Co. and Oppenheimer & Co. Inc. are managing the offering. Capricor says the company plans to use the funds for product development, manufacturing, working capital, and general corporate purposes.

Stock Of The Day: Taiwan Semiconductor Breaks Out As Buyers Push Prices Higher

Should I Sell My CAPR Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Capricor Therapeutics stock currently has an RSI of 61.26, indicating neutral conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.